vendredi 24 janvier 2020

Onco Actu du 24 janvier 2020


1. BIOLOGIE



Why cells need acidic lysosomes [The Rockefeller University]











Preventing metastasis by stopping cancer cells from making fat [UC Louvain]











1.4 BIOLOGIE - TECHNOS, MODÈLES



‘We need a people’s cryo-EM.’ Scientists hope to bring revolutionary microscope to the masses [Science]











2.6 ETIOLOGIE - ENVIRONNEMENT



Bayer Shares up 2.3% on report about possible glyphosate settlement [Reuters]











3.1 PRÉVENTION - TABAC



Surgeon General's Report on Smoking Cessation Highlights Evidence-Based Ways to Help People Quit [ASCO]











E-cigarettes don't help smokers quit, U.S. Surgeon General says [UPI]











Surgeon General Releases First Report Focused on Smoking Cessation in 30 Years [HHS]










4.12 BIOPSIES LIQUIDES



Viral Cancer Early Detection Efforts Making Progress Toward the Clinic [Genome Web]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Imaging and New Technologies in Immunotherapy [Cancer Research Catalyst]










4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



23andMe laying off 14% of employees amid slump in DNA spit kit sales [STAT]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer [Roche]










Roche's Tecentriq fails trial in form of urothelial cancer [Reuters]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Merck KGaA spinout iOnctura raises cash for cancer trials [Fierce Biotech]











Merck KGaA spinout gets first funding to bring dual-acting cancer molecules into the clinic [EndPoints]











5.2 PHARMA



Eli Lilly’s $1.6B cancer drug failed to spark even the slightest positive gain for patients in its 1st PhIII [EndPoints]











5.3 TRAITEMENTS - FDA, EMA,...



The FDA has devalued the gold standard on R&D. And that threatens everyone in drug development [EndPoints]










5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Roche cracks China's ADC market open as Kadcyla scores its first breast cancer OK in the country [EndPoints]











5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - EPIZYME



Epizyme’s Soft Tissue Cancer Drug Granted Speedy FDA Approval [Xconomy]











Epizyme drug granted approval by FDA for rare cancer [Biopharma Dive]











FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer [FDA]










Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma [Epizyme]











Epizyme prices rare tissue cancer treatment at $15,500 a month [Reuters]











5.4 TRAITEMENTS - ECONOMIE



NICE declines to recommend Astellas' Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia [Pharmafile]